Matches in SemOpenAlex for { <https://semopenalex.org/work/W2433235065> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2433235065 endingPage "3" @default.
- W2433235065 startingPage "1230" @default.
- W2433235065 abstract "To explore the clinical efficacy and prognosis of the patients with intermediate risk gastric stromal tumor (GST).The data of intermediate risk GST patients confirmed by pathology and immunohistochemistry at Center of Gastrointestinal Surgery, West China Hospital, Sichuan University, between January 2007 and July 2011 were collected and retrospectively analyzed. And univariate and multivariate analyses were performed to assess the efficacy of imatinib mesylate (IM) according to recurrence-free survival (RFS).A total of 46 intermediate risk GST patients were enrolled with a median follow-up period of 31 (9-64) months. Among them, 20 patients received IM treatment and 1 had hepatic metastasis at 16 months after withdrawal. In contrast, 5 of 26 patients refusing IM treatment recurred or had a distant metastasis. The 1-, 2-, 3-year recurrence-free survival in IM treatment group and no IM treatment group were: 20/20 vs 25/26, 14/14 vs 17/20 and 6/7 vs 10/14, respectively. Cox proportion hazards regression: hazard ratio(HR) = 0.265, 95%CI: 0.025-2.761, P = 0.267. Among 6 patients with recurrence and(or) metastasis, 5 had mitotic count > 5/50 HPF. Cox proportion hazards regression (HR = 0.059, 95%CI: 0.004 - 0.976, P = 0.048) showed that IM can improve the progression free survival of mitotic count > 5/50 HPF group versus mitotic count < 5/50 HPF. The most common IM-related side effects were edema, nausea, abdominal discomfort, leukemia, etc. Most of them were Grade 1-2.Intermediate risk GST has a low rate of recurrence or metastasis. And 1-year IM treatment may improve the prognosis of the patients with mitotic counts > 5/50 HPF. Furthermore, IM treatment is safe in intermediate risk GST patients." @default.
- W2433235065 created "2016-06-24" @default.
- W2433235065 creator A5011877804 @default.
- W2433235065 creator A5014330983 @default.
- W2433235065 creator A5017825677 @default.
- W2433235065 creator A5017972853 @default.
- W2433235065 creator A5021847587 @default.
- W2433235065 creator A5068049800 @default.
- W2433235065 date "2013-04-23" @default.
- W2433235065 modified "2023-09-26" @default.
- W2433235065 title "[Clinical analysis of efficacy and prognosis of intermediate risk gastric stromal tumor patients]." @default.
- W2433235065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23902613" @default.
- W2433235065 hasPublicationYear "2013" @default.
- W2433235065 type Work @default.
- W2433235065 sameAs 2433235065 @default.
- W2433235065 citedByCount "0" @default.
- W2433235065 crossrefType "journal-article" @default.
- W2433235065 hasAuthorship W2433235065A5011877804 @default.
- W2433235065 hasAuthorship W2433235065A5014330983 @default.
- W2433235065 hasAuthorship W2433235065A5017825677 @default.
- W2433235065 hasAuthorship W2433235065A5017972853 @default.
- W2433235065 hasAuthorship W2433235065A5021847587 @default.
- W2433235065 hasAuthorship W2433235065A5068049800 @default.
- W2433235065 hasConcept C121608353 @default.
- W2433235065 hasConcept C126322002 @default.
- W2433235065 hasConcept C141071460 @default.
- W2433235065 hasConcept C143998085 @default.
- W2433235065 hasConcept C144301174 @default.
- W2433235065 hasConcept C207103383 @default.
- W2433235065 hasConcept C2777583451 @default.
- W2433235065 hasConcept C2778729363 @default.
- W2433235065 hasConcept C2779013556 @default.
- W2433235065 hasConcept C2780580376 @default.
- W2433235065 hasConcept C3019892230 @default.
- W2433235065 hasConcept C38180746 @default.
- W2433235065 hasConcept C44249647 @default.
- W2433235065 hasConcept C50382708 @default.
- W2433235065 hasConcept C71924100 @default.
- W2433235065 hasConcept C90924648 @default.
- W2433235065 hasConceptScore W2433235065C121608353 @default.
- W2433235065 hasConceptScore W2433235065C126322002 @default.
- W2433235065 hasConceptScore W2433235065C141071460 @default.
- W2433235065 hasConceptScore W2433235065C143998085 @default.
- W2433235065 hasConceptScore W2433235065C144301174 @default.
- W2433235065 hasConceptScore W2433235065C207103383 @default.
- W2433235065 hasConceptScore W2433235065C2777583451 @default.
- W2433235065 hasConceptScore W2433235065C2778729363 @default.
- W2433235065 hasConceptScore W2433235065C2779013556 @default.
- W2433235065 hasConceptScore W2433235065C2780580376 @default.
- W2433235065 hasConceptScore W2433235065C3019892230 @default.
- W2433235065 hasConceptScore W2433235065C38180746 @default.
- W2433235065 hasConceptScore W2433235065C44249647 @default.
- W2433235065 hasConceptScore W2433235065C50382708 @default.
- W2433235065 hasConceptScore W2433235065C71924100 @default.
- W2433235065 hasConceptScore W2433235065C90924648 @default.
- W2433235065 hasIssue "16" @default.
- W2433235065 hasLocation W24332350651 @default.
- W2433235065 hasOpenAccess W2433235065 @default.
- W2433235065 hasPrimaryLocation W24332350651 @default.
- W2433235065 hasRelatedWork W1533422205 @default.
- W2433235065 hasRelatedWork W1987257015 @default.
- W2433235065 hasRelatedWork W2120574916 @default.
- W2433235065 hasRelatedWork W2142544041 @default.
- W2433235065 hasRelatedWork W2558534037 @default.
- W2433235065 hasRelatedWork W2760851598 @default.
- W2433235065 hasRelatedWork W2887874983 @default.
- W2433235065 hasRelatedWork W3009255790 @default.
- W2433235065 hasRelatedWork W4281560766 @default.
- W2433235065 hasRelatedWork W4283321516 @default.
- W2433235065 hasVolume "93" @default.
- W2433235065 isParatext "false" @default.
- W2433235065 isRetracted "false" @default.
- W2433235065 magId "2433235065" @default.
- W2433235065 workType "article" @default.